A review of studies shows that cannabinoids have significant anticancer potential by limiting tumor growth, inducing cancer cell death, and improving chemotherapy effectiveness. While cannabinoids are already widely used in palliative care for cancer patients to manage symptoms like pain and nausea, further large-scale studies are required to confirm their direct role in cancer treatment.
A new scientific review has revealed the promising potential of cannabinoids such as THC, CBD, and CBG in cancer treatment.
Researchers concluded that these compounds can limit tumor growth and prevent the spread of cancer, highlighting their potential as anticancer agents. While this research is promising, scientists acknowledge that much remains to be understood about how these cannabinoids work and what the optimal dosage might be.
For more news like this, along with all the latest in legalization, research, and lifestyle, download our free cannabis news app.
According to a review of studies published in Discover Oncology, cannabinoids have demonstrated significant anticancer properties.
These compounds can induce apoptosis (programmed cell death), stimulate autophagy (the body’s way of clearing damaged cells), and halt the cell cycle.
Additionally, cannabinoids have shown anti-proliferative, anti-angiogenesis, and metastasis-inhibiting properties, all critical for stopping the spread of cancer cells. Cannabinoids have also been effective in palliative care, helping regulate appetite, manage pain, and provide anti-nausea effects for patients undergoing chemotherapy.
Although clinical trials have confirmed the efficacy of cannabinoids in tumor regression and improving health outcomes, researchers emphasize that the mechanisms behind these effects are not fully understood. They call for more research to understand how cannabinoids interact with cancer cells and influence the tumor environment.
The study notes that while many cancer patients already use cannabis, particularly in palliative care, there is a need for more large-scale, randomized controlled trials. These studies would validate the therapeutic effects of cannabinoids and develop standardized treatments for cancer patients.
There is growing evidence that cannabinoids may enhance the efficacy of traditional cancer treatments like chemotherapy. Among the reviewed studies, some suggest that combining CBD and THC with chemotherapy drugs such as cisplatin, gemcitabine, and paclitaxel can increase the cytotoxic effects of these drugs, leading to greater cancer cell death. By modulating pathways involved in cell cycle regulation and apoptosis, cannabinoids may make cancer cells more susceptible to chemotherapy-induced death.
This potential synergy between cannabinoids and chemotherapy paves the way for further exploration of how cannabis could be used as an adjunct therapy in cancer treatment. However, like other aspects of cannabinoid use, this area requires more research to clarify the interactions and establish consistent clinical guidelines.
In addition to well-known cannabinoids like THC and CBD, lesser-known compounds such as CBG, CBC, CBN, and CBDV are also showing promise as anticancer agents. A separate study published in BioFactors explored the potential of these minor cannabinoids in treating multiple myeloma (MM), a type of blood cancer.
The study tested responses in cell models and found that all four cannabinoids had cytotoxic effects on MM cells. CBN was also tested in a mouse model and showed potential for in vivo application, suggesting that these lesser-known cannabinoids may have untapped therapeutic potential.
These findings highlight the diversity of cannabinoids and their potential roles in oncology. While most research has focused on THC and CBD, increasing evidence suggests that minor cannabinoids could provide valuable tools in the fight against cancer.
Despite these promising results, significant gaps remain regarding how cannabinoids work at the cellular level. Understanding the signaling pathways and how these compounds affect the tumor microenvironment is essential for fully harnessing their therapeutic potential.
The authors of the Discover Oncology review stress that research on cannabinoids and cancer is still in its early stages. While medicinal cannabis use dates back centuries, modern scientific research on the anticancer properties of cannabinoids is relatively new. A better understanding of how cannabinoids interact with cancer cells could lead to more effective cancer treatments.
Cannabinoids are widely used in palliative care, particularly for cancer patients undergoing chemotherapy. Cannabis-based products help regulate appetite, manage pain, and combat nausea, making them a valuable complement to treatment plans aimed at improving patients’ quality of life.
While cannabis is commonly used to alleviate the side effects of cancer treatments, researchers are also exploring whether cannabinoids might play a direct role in treating the disease itself. According to a 2019 study, cannabis may slow the growth of cancer cells and, in some cases, kill them outright. However, the study noted that most of this research has been conducted in vitro (outside a living organism), so more studies involving human subjects are needed.
—
(Featured image by National Cancer Institute via Unsplash)
DISCLAIMER: This article was written by a third-party contributor and does not reflect the opinion of Hemp.im, its management, staff, or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the company may believe that its expectations are based on reasonable assumptions, the actual results that the company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in Newsweed, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Berlin is launching a pilot project in the Friedrichshain-Kreuzberg and Neukölln districts to study the…
The Czech Constitutional Court overturned a previous ruling accusing Robert Veverka, former editor of Legalizace,…
U.N. High Commissioner for Human Rights Volker Türk has declared the war on drugs a…
Pennsylvania lawmakers have proposed a plan to legalize recreational cannabis by 2025. Projections estimate up…
The DEA just held its first procedural hearing on cannabis reclassification, although the focus was…
The Superior Court of Justice in Brazil has legalized the cultivation, processing, and sale of…